Cryptic B cell response to renal transplantation

American Journal of Transplantation

Volumn 13, Issue 7, 2013, Pages 1713-1723

  Lynch, R J ^a   Silva, I A ^a   Chen, B J ^a   Punch, J D ^a   Cascalho, M ^a,b   Platt, J L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

accommodation; rejection; renal transplant; tolerance

Indexed keywords

ALEFACEPT; BOVINE SERUM ALBUMIN; CYCLOSPORIN; FLUORESCEIN ISOTHIOCYANATE; HLA ANTIBODY; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL FATE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTER; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTIBODY-PRODUCING CELLS; B-LYMPHOCYTES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNITY, CELLULAR; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MICE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879553714     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12308     Document Type: Article

References (63)

1. Gorer PA., The antigenic basis of tumour transplantation. J Pathol Bacteriol 1938; 47: 231-252.
2. Gorer PA., The antibody response to skin homografts in mice. Ann NY Acad Sci 1955; 59: 365-373.
3. Gorer P., Some recent work on tumor immunity. Adv Cancer Res 1956; 4: 149-186.
4. Stetson CA., The role of humoral antibody in the homograft reaction. Adv Immunol 1963; 3: 97-130.
5. Auchincloss H, Jr., Ghobrial RR, Russell PS, Winn HJ., Prevention of alloantibody formation after skin grafting without prolongation of graft survival by anti-L3T4 in vivo. Transplantation 1988; 45: 1118-1123.
6. Klein J, Chiang C, Lofgreen J, Steinmuller D., Participation of H-2 regions in heart-transplant rejection. Transplantation 1976; 22: 384-390.
7. Amos DB, Gorer PA, Mikulska BM, Billingham RE, Sparrow EM., An antibody response to skin homografts in mice. Br J Exp Pathol 1954; 35: 203-208.
8. Klein J, Hauptfeld V, Hauptfeld M., Evidence for a third, IR-associated histocompatibility region in the H-2 complex of the mouse. Immunogenetics 1974; 1: 45-56.
9. Klein J, Geib R, Chiang C, Hauptfeld V., Histocompatibility antigens controlled by the I region of the murine H-2 complex. I. Mapping of H-2A and H-2C loci. J Exp Med 1976; 143: 1439-1452.
10. Snell GD., The genetics of transplantation. J Natl Cancer Inst 1953; 14: 691-704.
11. Terasaki P, McClelland JP., Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998-1000.
12. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315-323.
13. Martin S, Dyer PA, Mallick NP, Gokal R, Harris R, Johnson RW., Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50-53.
14. Halloran PF, Schlaut J, Solez K, Srinivasa NS., The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
15. Scornik JC, Salomon DR, Lim PB, Howard RJ, Pfaff WW., Posttransplant antidonor antibodies and graft rejection. Evaluation by two-color flow cytometry. Transplantation 1989; 47: 287-290.
16. Christiaans MH, Overhof-de Roos R, Nieman F, van Hooff JP, van den Berg-Loonen EM., Donor-specific antibodies after transplantation by flow cytometry: Relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 1998; 65: 427-433.
17. Varnavidou-Nicolaidou A, Iniotaki-Theodoraki AG, Doxiadis II, et al. Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome. Hum Immunol 2005; 66: 985-988.
18. Cardarelli F, Pascual M, Tolkoff-Rubin N, et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transplant Int 2005; 18: 532-540.
19. Zhang Q, Liang LW, Gjertson DW, et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79: 591-598.
20. Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011; 72: 5-10.
21. Li X, Ishida H, Yamaguchi Y, Tanabe K., Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation. Transplant Int 2008; 21: 1145-1152.
22. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312-319.
23. Hirai T, Kohei N, Omoto K, Ishida H, Tanabe K., Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transplant Int 2012; 25: 925-934.
24. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K., Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469-476.
25. Nemazee DA, Burki K., Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989; 337: 562-566.
26. Goodnow CC, Crosbie J, Jorgensen H, Brink RA, Basten A., Induction of self-tolerance in mature peripheral B lymphocytes. Nature 1989; 342: 385-391.
27. Fan X, Ang A, Pollock-BarZiv SM, et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004; 10: 1227-1233.
28. Mohanakumar T, Waldrep JC, Phibbs M, Mendez-Picon G, Kaplan AM, Lee HM., Serological characterization of antibodies eluted from chronically rejected human renal allografts. Transplantation 1981; 32: 61-66.
29. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G., Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395-400.
30. Briggs D, Zehnder D, Higgins RM., Development of non-donor-specific HLA antibodies after kidney transplantation: Frequency and clinical implications. Contrib Nephrol 2009; 162: 107-116.
31. Higgins R, Lowe D, Hathaway M, et al. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. Transplantation 2009; 87: 882-888.
32. Ishida H, Hirai T, Kohei N, Yamaguchi Y, Tanabe K., Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation. Transplant Int 2011; 24: 150-157.
33. Collins BH, Cotterell AH, McCurry KR, et al. Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. J Immunol 1995; 154: 5500-5510.
34. McCurry KR, Parker W, Cotterell AH, et al. Humoral responses to pig-to-baboon cardiac transplantation: Implications for the pathogenesis and treatment of acute vascular rejection and for accommodation. Hum Immunol 1997; 58: 91-105.
35. Sedgwick JD, Holt PG., A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 57: 301-309.
36. Czerkinsky CC, Nilsson L, Nygren H, Ouchterlony O, Tarkowski A., A solid-phase enzyme-linked immunospot (ElISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 65: 109-121.
37. Tarkowski A, Czerkinsky C, Nilsson LA., Simultaneous induction of rheumatoid factor- and antigen-specific antibody-secreting cells during the secondary immune response in man. Clin Exp Immunol 1985; 61: 379-387.
38. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133-143.
39. Heidt S, Roelen DL, de Vaal YJ, et al. A NOVel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals. Am J Transplant 2012; 12: 1469-1478.
40. Bernasconi NL, Traggiai E, Lanzavecchia A., Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-2202.
41. Jourdan M, Caraux A, De Vos J, et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009; 114: 5173-5181.
42. Parker W, Bruno D, Holzknecht ZE, Platt JL., Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153: 3791-3803.
43. Larson LN, Johansson C, Lindholm L., Localization of antibody-secreting cells against human colon adenocarcinoma cell lines using the enzyme-linked immunospot assay. Int Arch Allergy Appl Immunol 1988; 87: 405-408.
44. Schneider YJ, Tulkens P, de Duve C, Trouet A., Fate of plasma membrane during endocytosis. I. Uptake and processing of anti-plasma membrane and control immunoglobulins by cultured fibroblasts. J Cell Biol 1979; 82: 449-465.
45. Mantovani B, Rabinovitch M, Nussenzweig V., Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med 1972; 135: 780-792.
46. Platt JL, Cascalho M., Donor specific antibodies after transplantation. Pediatr Transplant 2011; 15: 686-690.
47. Zhou ZH, Notkins AL., Polyreactive antigen-binding B (PAB-) cells are widely distributed and the PAB population consists of both B-1+ and B-1- phenotypes. Clin Exp Immunol 2004; 137: 88-100.
48. Zhou ZH, Tzioufas AG, Notkins AL., Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun 2007; 29: 219-228.
49. Mestre M, Massip E, Bas J, et al. Longitudinal study of the frequency of cytotoxic T cell precursors in kidney allograft recipients. Clin Exp Immunol 1996; 104: 108-114.
50. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Lechler RI., The role of the allograft in the induction of donor-specific T cell hyporesponsiveness. Transplantation 2001; 72: 480-485.
51. Stiver HG, Graves P, Meiklejohn G, Schroter G, Eickhoff TC., Impaired serum antibody response to inactivated influenza A and B vaccine in renal transplant recipients. Infect Immun 1977; 16: 738-741.
52. Admon D, Engelhard D, Strauss N, Goldman N, Zakay-Rones Z., Antibody response to influenza immunization in patients after heart transplantation. Vaccine 1997; 15: 1518-1522.
53. Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009; 9: 2346-2354.
54. Meyer S, Adam M, Schweiger B, et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011; 91: 1031-1035.
55. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
56. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC., Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103-1109.
57. Everett ML, Lin SS, Worrell SS, Platt JL, Parker W., The footprint of antibody bound to pig cells: Evidence of complex surface topology. Biochem Biophys Res Commun 2003; 301: 751-757.
58. Parker W, Stitzenberg KB, Yu PB, et al. Biophysical characteristics of anti-Gal(alpha)1-3Gal IgM binding to cell surfaces: Implications for xenotransplantation. Transplantation 2001; 71: 440-446.
59. Platt JL, LeBien TW, Michael AF., Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens. J Exp Med 1983; 157: 155-172.
60. Lynch RJ, Platt JL., Accommodation in organ transplantation. Curr Opin Organ Transplant 2008; 13: 165-170.
61. Pelletier RP, Hennessy PK, Adams PW, VanBuskirk AM, Ferguson RM, Orosz CG., Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2: 134-141.
62. Koch CA, Khalpey ZI, Platt JL., Accommodation: Preventing injury in transplantation and disease. J Immunol 2004; 172: 5143-5148.
63. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: A review of progress. Immunol Today 1990; 11: 450-457.